Is eribulin treatment prognostic factor in patients with metastatic breast cancer treated with this drug? Retrospective analysis of a multicentre study
dc.contributor.author | Oruc, Z; Kaplan, MA; Geredeli, C; Sari, NY; Ozaslan, E; Aytekin, A; Elkiran, ET; Koca, S; Dogan, M; Turan, N; Yuce, O; Sevinc, A; Ercelep, O; Isikdogan, A | |
dc.date.accessioned | 2023-03-02T06:39:05Z | |
dc.date.available | 2023-03-02T06:39:05Z | |
dc.date.issued | MAR-APR | |
dc.date.issued | 2020 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12481/14323 | |
dc.description.abstract | Purpose: This study aimed to analyze prognostic factors for survival and the reliability and the effectiveness of eribulin therapy in metastatic breast cancer (MBC) patients. Methods: A total of 80 patients treated with eribulin in 12 medical oncology centers in Turkey between 2013-2017 were retrospectively evaluated. Sixteen potential prognostic variables were assessed for analysis. Results: The patients had received a median of 5 prior chemotherapy regimens and a median of 3 eribulin cycles for MBC. Median progression free survival (PFS) was 5.5 months (95% CI: 4.1-7.8) and median overall survival (OS) was 11 months (95 % CI: 6-15). Multivariate analysis showed that eribulin treatment line was shown to have independent prognostic significance for PFS. PFS difference was demostrated in patients who received 3 chemotherapy lines for advanced disease compared to those who had more than 3 chemotherapy lines [median PFS; 3 lines: 8.6 months (6.2-11) and >3 lines: 4.6 months (3.7-16) p=0.00]. The clinical benefit rate (CBR) was 52.5 and 35% in patients treated with three lines and with >3 previous chemotherapeutic regimens. Most common toxicities were neutropenia (62.5%), fatigue (52.5%), alopecia (50%) and nausea (37.5%). Conclusions: Eribulin treatment line was identified as indepedent prognostic factor for PFS in MBC patients. | |
dc.title | Is eribulin treatment prognostic factor in patients with metastatic breast cancer treated with this drug? Retrospective analysis of a multicentre study | |
dc.title.alternative | JOURNAL OF BUON | |
dc.identifier.volume | 25 | |
dc.identifier.issue | 2 | |
dc.identifier.startpage | 641 | |
dc.identifier.endpage | 647 | |
dc.identifier.issn/e-issn | 1107-0625 | |
dc.identifier.issn/e-issn | 2241-6293 |
Bu öğenin dosyaları:
Dosyalar | Boyut | Biçim | Göster |
---|---|---|---|
Bu öğe ile ilişkili dosya yok. |
Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.
-
Web Of Science [8594]
Web Of Science indeksli Yayınlar Koleksiyonu